These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33422578)

  • 1. Role of community pharmacies in a population-based colorectal cancer screening program.
    Vives N; Milà N; Binefa G; Travier N; Farre A; Vidal C; Sattari M; Bagaria G; Garcia M
    Prev Med; 2021 Apr; 145():106420. PubMed ID: 33422578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
    Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
    Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Colorectal Cancer Early Screening Program of Barcelona, Spain: Indicators of the first round of a program with participation of community pharmacies].
    Burón A; Grau J; Andreu M; Augé JM; Guayta-Escolies R; Barau M; Macià F; Castells A;
    Med Clin (Barc); 2015 Aug; 145(4):141-6. PubMed ID: 25073826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacist intervention in colorectal cancer screening initiative.
    Holle LM; Levine J; Buckley T; White CM; White C; Hadfield MJ
    J Am Pharm Assoc (2003); 2020; 60(4):e109-e116. PubMed ID: 32197754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the appropriateness of a community pharmacy model for a colorectal cancer screening program in Catalonia (Spain).
    Santolaya M; Aldea M; Grau J; Estrada M; Barau M; Buron A; Francesc M; Castell A; Rodriguez C; Gascón P; Rius P; Guayta-Escolies R;
    J Oncol Pharm Pract; 2017 Jan; 23(1):26-32. PubMed ID: 26563130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient perspectives on a proposed pharmacy-based colorectal cancer screening program.
    Ferrari RM; Atkins DL; Wangen M; Rohweder CL; Waters AR; Correa S; Richmond J; van Rensburg D; Ittes A; Odebunmi O; Issaka RB; Ceballos R; Shah PD; Wheeler SB; Brenner AT
    Transl Behav Med; 2023 Dec; 13(12):909-918. PubMed ID: 37756664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Finding the Right FIT": Rural Patient Preferences for Fecal Immunochemical Test (FIT) Characteristics.
    Pham R; Cross S; Fernandez B; Corson K; Dillon K; Yackley C; Davis MM
    J Am Board Fam Med; 2017; 30(5):632-644. PubMed ID: 28923816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and cost of multilayered colorectal cancer screening promotion interventions at federally qualified health centers in Washington State.
    Kemper KE; Glaze BL; Eastman CL; Waldron RC; Hoover S; Flagg T; Tangka FKL; Subramanian S
    Cancer; 2018 Nov; 124(21):4121-4129. PubMed ID: 30359468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the faecal immunochemical test on colorectal cancer survival.
    Gutierrez-Stampa MA; Aguilar V; Sarasqueta C; Cubiella J; Portillo I; Bujanda L
    BMC Cancer; 2020 Jul; 20(1):616. PubMed ID: 32611328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program.
    Chiu HM; Chen SL; Yen AM; Chiu SY; Fann JC; Lee YC; Pan SL; Wu MS; Liao CS; Chen HH; Koong SL; Chiou ST
    Cancer; 2015 Sep; 121(18):3221-9. PubMed ID: 25995082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Feasibility of colorectal cancer screening with fecal occult blood test distributed by public pharmacies].
    Pippa G; Ferrara M; Valle S; Diego B; Alessandra B; Apuzzo M; Bazuro ME; Tammaro G; Federici A
    Recenti Prog Med; 2009; 100(7-8):348-51. PubMed ID: 19725474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated screening for colorectal cancer with fecal occult blood test in Catalonia, Spain.
    Garcia M; Borràs JM; Binefa G; Milà N; Espinàs JA; Moreno V
    Eur J Cancer Prev; 2012 Jan; 21(1):42-5. PubMed ID: 21849903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population.
    Malagón M; Ramió-Pujol S; Serrano M; Amoedo J; Oliver L; Bahí A; Miquel-Cusachs JO; Ramirez M; Queralt-Moles X; Gilabert P; Saló J; Guardiola J; Piñol V; Serra-Pagès M; Castells A; Aldeguer X; Garcia-Gil LJ
    PLoS One; 2020; 15(12):e0243158. PubMed ID: 33259546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual and Geospatial Characteristics Associated With Use and Nonuse of the Fecal Immunochemical Test (FIT) for Colorectal Cancer Screening in an Urban Minority Population.
    Ramai D; Etienne D; Ayide G; Fields PJ; Reddy M
    J Clin Gastroenterol; 2019; 53(10):744-749. PubMed ID: 30222644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
    Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
    JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary care provider perspectives on the role of community pharmacy in colorectal cancer screening: a qualitative study.
    Brenner AT; Rohweder CL; Wangen M; Atkins DL; Ceballos RM; Correa S; Ferrari RM; Issaka RB; Ittes A; Odebunmi OO; Reuland DS; Waters AR; Wheeler SB; Shah PD
    BMC Health Serv Res; 2023 Aug; 23(1):892. PubMed ID: 37612656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
    Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal cancer screening program implementation: biennial adherence and participation patterns.
    Priego-Parra BA; Triana-Romero A; Inurreta-Vásquez A; Laffitte-García H; Violante-Hernández GA; Jiménez-Rodríguez SS; Martínez-Pérez GP; Meixueiro-Daza A; Grube-Pagola P; Remes-Troche JM
    Rev Gastroenterol Mex (Engl Ed); 2024; 89(3):354-361. PubMed ID: 38862361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow-up approaches to a health literacy intervention to increase colorectal cancer screening in rural community clinics: A randomized controlled trial.
    Arnold CL; Rademaker AW; Morris JD; Ferguson LA; Wiltz G; Davis TC
    Cancer; 2019 Oct; 125(20):3615-3622. PubMed ID: 31355924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.